ASE·Healthcare·$186M·#232 / 520 in Healthcare
PLX Protalix BioTherapeutics, Inc.
47SPECULATIVE
CATEGORY BREAKDOWN
GROWTH0
QUALITY45
STABILITY63
VALUATION93
GOVERNANCE52
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-1.2%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
48.8%
68
> 50% strong
Cash Runway
Months of cash at current burn rate
15 months
51
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
17.3%
86
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.4x
93
< 3x strong
Rule of 40
Growth rate plus operating margin
-12
11
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.9%
31
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+1.1%
94
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE PLX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when PLX's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.